Sanofi has paid big bucks to enter the race to develop a new drug for MS. The drug was developed by Principia Biopharma and crosses the blood-brain barrier making it an attractive candidate not only for MS but for the treatment of other neurological disease.
| less than a minute read
Sanofi Enters the Race to Develop a New Drug for Multiple Sclerosis
Get in touch
Get in touch
Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma. The French Big Pharma is paying $40 million upfront to pick up the preclinical asset, with $765 million more to follow if it passes all the milestones that await.
Tweets on this subject
Sanofi has committed up to $805 million to license a preclinical multiple sclerosis drug from Principia Biopharma: https://t.co/U8JT3n6ucA
— FierceBiotech (@FierceBiotech) November 9, 2017
Sanofi pays $40M, commits $765M more for preclinical MS drug https://t.co/l9ruH5YDQg pic.twitter.com/4o5lK4xeu5
— BioCalifornia (@BioCalifornia) November 9, 2017
Get in touch
Get in touch
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/5ed622ef8cb62a041c7fddf8/2023-06-05-13-03-58-587-647ddd3ebf5f681be5eb3dc6.jpg)
The DLA Piper Life Sciences sector team is delighted to announce the launch of our new 2023 Global M&A Intelligence Report – Life...
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2023-09-28-15-40-49-398-65159e8167137e2e6d34f2b2.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2023-09-20-09-27-45-948-650abb11d80b7c8fbe6f217f.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2023-09-18-08-50-41-355-65080f616339aae19fcc0b02.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2023-09-14-14-37-32-529-65031aac385f205e18c2d233.jpg)
